Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009;3(5):e432.
doi: 10.1371/journal.pntd.0000432. Epub 2009 May 5.

WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study

Afif Ben Salah  1 , Pierre A Buffet, Gloria Morizot, Nathalie Ben Massoud, Amor Zâatour, Nissaf Ben Alaya, Nabil Bel Haj Hamida, Zaher El Ahmadi, Matthew T Downs, Philip L Smith, Koussay Dellagi, Max Grögl
Affiliations
Clinical Trial

WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study

Afif Ben Salah et al. PLoS Negl Trop Dis. 2009.

Abstract

Background: Cutaneous leishmaniasis (cl) is a disfiguring disease that confronts clinicians with a quandary: leave patients untreated or engage in a complex or toxic treatment. Topical treatment of CL offers a practical and safe option. Accordingly, the treatment of CL with WR279,396, a formulation of paromomycin and gentamicin in a hydrophilic base, was investigated in a phase 2 clinical study in Tunisia and France.

Methods: A phase 2, randomized, double blind, vehicle-controlled study was conducted to assess the safety and efficacy of topical WR279,396 when applied twice a day for 20 days as treatment for parasitologically confirmed CL. The study protocol established the primary efficacy end point as complete clinical response (CCR) defined as 50% or greater reduction in the ulceration size of an index lesion by day 50 (D50) followed by complete re-epithelialization by D100, and no relapse through D180.

Results: Ninety-two subjects were randomized. Leishmania major was identified in 66 of 68 isolates typed (97%). In the intent-to-treat population, 47 of 50 WR279,396 treated participants (94%) met the definition of CCR, compared with 30 of 42 vehicle-placebo participants (71%) [p = 0.0045]. Erythema occurred in 30% and 24% of participants receiving WR279,396 and placebo, respectively [p = 0.64]. There was no clinical or laboratory evidence of systemic toxicity.

Conclusion: Application of WR279,396 for 20 days was found to be safe and effective in treating L. major CL, and offers great potential as a new, simple, easily applicable, and inexpensive topical therapy for this neglected disease.

Trial registration: ClinicalTrials.gov NCT00703924.

PubMed Disclaimer

Conflict of interest statement

Patent-Actual: As a member of the US Army, MG received $200 when he signed the patent to the US Army. MG has no financial competing interests and would like to see this product approved by the FDA for the good of the soldiers and people in endemic countries.

Figures

Figure 1
Figure 1. Flowchart summarizing the enrolment, randomization and follow-up of patients.
Values are numbers of patients as follows: Total number of patients (Number at Tunisian site/number at French site).
Figure 2
Figure 2. Reepithelialization of index lesion without relapse.
See this image and copyright information in PMC

References

    1. Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat Q. 1992;45:267–275. - PubMed
    1. Magill AJ. Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am. 2005;19:x–xi. - PubMed
    1. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004;53:158–166. - PubMed
    1. Buffet P, Caumes E, Gentilini M. [Treatment of localized cutaneous leishmaniasis]. Ann Dermatol Venereol. 1994;121:503–511. - PubMed
    1. Belazzoug S, Neal RA. Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria [letter]. Trans R Soc Trop Med Hyg. 1986;80:670–671. - PubMed

Publication types

MeSH terms

Associated data